![]() Total revenues were $210.6 million in the third quarter of 2022 compared to $158.1 million for the third quarter of 2021, an increase of 33.2%. Third Quarter Ended SeptemFinancial Results Published inaugural Environmental, Social and Governance ("ESG") report reinforcing the Company's commitment to these areas and establishing 2025 goals. Prospera™ Kidney Test shown to outperform DSA in predicting antibody mediated rejection in Trifecta study published in Transplantation. Department of Veterans Affairs.Ĭontinued MRD data leadership for Signatera™ with new published studies in ovarian and uveal melanoma, CIRCULATE study accepted in Nature Medicine with 18-month prospective follow-up, and large (N=943) gastro-esophageal study accepted in JCO Precision Oncology. Immunotherapy monitoring Medicare reimbursement set at $7,489 awarded pan-cancer Signatera™ contract from the U.S. Performed 53,000 oncology tests in the third quarter of 2022, representing 153% growth compared to the third quarter of 2021, with 35 published peer-reviewed studies for Signatera™ to date. Processed approximately 517,500 tests in the third quarter of 2022, compared to approximately 407,300 tests in the third quarter of 2021, an increase of 27.1%.Ģ022 revenue guidance raised to $810 million – $830 million, up $40 million vs. Product revenues grew 29.8% over the same period. Generated total revenues of $210.6 million in the third quarter of 2022 compared to $158.1 million in the third quarter of 2021, an increase of 33.2%. Recent Strategic and Financial Highlights ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
March 2023
Categories |